-25%

est. 2Y upside i

Data & AnalyticsAI & MLSeries A

Collate uses AI to create and streamline paperwork for diagnostic, medical device, and drug development companies—from concept to market. Our mission is to accelerate life-saving innovations by creating accurate documentation for the life sciences industry.

Rank

#82

Sector

Data Intelligence, AI/ML, SaaS

Est. Liquidity

~5Y

Data Quality

Data: Medium

Collate presents a strong upside opportunity driven by its exceptional 350% YoY growth and a robust competitive moat built around its OpenMetadata open-source project and AI-powered platform.

Last updated: March 10, 2026

Bull (35%)+400%

Collate's AI-powered agentic data intelligence platform, built on the rapidly growing OpenMetadata open-source core, achieves significant market penetration by displacing legacy data governance solutions and expanding into new enterprise segments. Strategic partnerships and continued AI innovation drive ARR to over $150M by 2028, justifying a $1.67B+ valuation at a premium multiple, well above the current $334M.

Base (40%)+100%

Collate maintains its high growth trajectory, leveraging its strong competitive moat and open-source advantage to capture a meaningful share of the data intelligence market. ARR reaches approximately $80M by 2028, leading to a successful Series B or C round at a valuation of around $668M, reflecting continued strong execution and market demand.

Bear (25%)-70%

Dominant incumbents like Microsoft and Salesforce aggressively integrate advanced AI data governance features, commoditizing parts of Collate's offering. This, combined with slower-than-expected enterprise adoption or increased competition from well-funded rivals, causes growth to decelerate significantly. A down round or acquisition at a reduced valuation of approximately $100M wipes out a substantial portion of common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

low

Investors hold $10M in liquidation preferences, which is only 3% of the estimated current valuation of $334M.

Dilution Risk

moderate

As a Series A company, Collate will likely undergo multiple future funding rounds, leading to further dilution for common shareholders.

Secondary Liquidity

none

Given its Series A stage, there is currently no active secondary market or tender offers for Collate's equity.

Questions to Ask at the Interview

Strategic questions based on Collate's data — designed to show you've done your homework.

  • 1

    “Given the strong incumbent threat from players like Microsoft and Salesforce, how does Collate plan to maintain its differentiation and capture market share beyond its open-source advantage?”

  • 2

    “With an estimated ARR of $20M and 350% YoY growth, what are the key strategic initiatives and product roadmap priorities for the next 12-24 months to sustain this growth trajectory and achieve the next funding milestone?”

  • 3

    “Considering the Series A funding in July 2025 and the typical venture capital timelines, what is the company's anticipated timeline and strategy for future funding rounds and a potential liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -25% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.